Drug intelligence / Profile preview

sevoflurane + nitrous oxide + oxygen

Development stage: Unknown
Modality: Small Molecules
Administration: Inhalation

Overview

A combination anesthetic mixture consisting of sevoflurane (a volatile anesthetic agent), nitrous oxide (an inhalational anesthetic), and oxygen. This combination is commonly used for inhalational induction and maintenance of general anesthesia, particularly in pediatric patients. The mixture provides rapid induction due to sevoflurane's pleasant non-irritating odor and low blood-gas solubility, while nitrous oxide is sometimes used to potentially enhance alveolar uptake of sevoflurane. It leverages the properties of each component to achieve effective anesthesia.

Targets

GABRR (GABA-A receptor subunit rho)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on sevoflurane + nitrous oxide + oxygen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sevoflurane + nitrous oxide + oxygen.

Explore the full profile